Noxa : Role in Cancer Pathogenesis and Treatment
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.org..
The B-cell lymphoma 2 (Bcl-2) family proteins play an important role in regulating apoptosis, or programmed cell death, in response to several extracellular and intracellular signals. These proteins are either pro-apoptotic or anti-apoptotic. The pro-apoptotic Noxa is a Bcl-2 family protein that belongs to a subclass of BH3-only proteins. Noxa induces apoptosis via p53-dependent and/or p53-independent mechanisms. While Noxa may play a limited role in apoptosis, it is a crucial player that interacts with several proteins in the apoptosis pathway, highlighting its importance in the pathogenesis and treatment of certain cancers. In this review, we will elucidate the mechanisms by which Noxa regulates apoptosis and review the roles of chemotherapeutic drugs in relation to Noxa.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Current cancer drug targets - 18(2018), 10 vom: 08., Seite 914-928 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Morsi, Rami Z [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.10.2019 Date Revised 22.10.2019 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1568009618666180308105048 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM281778590 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM281778590 | ||
| 003 | DE-627 | ||
| 005 | 20231225032422.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1568009618666180308105048 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0939.xml |
| 035 | |a (DE-627)NLM281778590 | ||
| 035 | |a (NLM)29521234 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Morsi, Rami Z |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Noxa |b Role in Cancer Pathogenesis and Treatment |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.10.2019 | ||
| 500 | |a Date Revised 22.10.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.org. | ||
| 520 | |a The B-cell lymphoma 2 (Bcl-2) family proteins play an important role in regulating apoptosis, or programmed cell death, in response to several extracellular and intracellular signals. These proteins are either pro-apoptotic or anti-apoptotic. The pro-apoptotic Noxa is a Bcl-2 family protein that belongs to a subclass of BH3-only proteins. Noxa induces apoptosis via p53-dependent and/or p53-independent mechanisms. While Noxa may play a limited role in apoptosis, it is a crucial player that interacts with several proteins in the apoptosis pathway, highlighting its importance in the pathogenesis and treatment of certain cancers. In this review, we will elucidate the mechanisms by which Noxa regulates apoptosis and review the roles of chemotherapeutic drugs in relation to Noxa | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a B-cell lymphoma 2 | |
| 650 | 4 | |a Bcl-2 | |
| 650 | 4 | |a Noxa | |
| 650 | 4 | |a apoptosis | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a p53. | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a BAD protein, human |2 NLM | |
| 650 | 7 | |a MCL1 protein, human |2 NLM | |
| 650 | 7 | |a Myeloid Cell Leukemia Sequence 1 Protein |2 NLM | |
| 650 | 7 | |a PMAIP1 protein, human |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-bcl-2 |2 NLM | |
| 650 | 7 | |a Tumor Suppressor Protein p53 |2 NLM | |
| 650 | 7 | |a bcl-Associated Death Protein |2 NLM | |
| 700 | 1 | |a Hage-Sleiman, Rouba |e verfasserin |4 aut | |
| 700 | 1 | |a Kobeissy, Hadile |e verfasserin |4 aut | |
| 700 | 1 | |a Dbaibo, Ghassan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current cancer drug targets |d 2001 |g 18(2018), 10 vom: 08., Seite 914-928 |w (DE-627)NLM120490560 |x 1873-5576 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2018 |g number:10 |g day:08 |g pages:914-928 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1568009618666180308105048 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2018 |e 10 |b 08 |h 914-928 | ||